Member of the board since 2022. Anders Jacobson, born 1967, has extensive experience in life science R&D and senior management. He is Chief Innovation Officer at the Swedish medical device company Senzime AB. Previously, he has held various senior positions in companies and on supervisory boards within Life Science and technical consulting for over 15 years. Anders brings deep expertise in life science focused research and development, manufacturing, and technical sales. Anders Jacobson owns no shares in Klaria Pharma.
Independent in relation to the major shareholders.
Independent in relation to the company and company management.
Member of the board since 2015. Scott Boyer is co-founder and CEO of Klaria. Prior to joining Klaria, he was Chief Scientist at AstraZeneca with global responsibility for molecular and investigational toxicology across Astra Zeneca and he was a member of the AZ senior management team. Prior to that, he was Senior Research Scientist at Pfizer. Scott Boyer has a Ph.D from the University of Colorado, Boulder in Molecular Toxicology. He completed a NIH Fogarty International Center Postdoctoral Fellowship at the Karolinska Institute. Scott Boyer owns 731 042 shares in Klaria Pharma.
Independent in relation to the major shareholders.
Dependent in relation to the company and company management.
